ProQR Therapeutics N.V
PRQR
Get informed when a big investor buys or sells
+ FollowMarket Cap$241.16M
Close$
$-0.67
132.2% downside
Current Fair Value
132.2% downsideOvervalued by 132.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $241.16 Million |
|---|---|
| Enterprise Value | $154.91 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.38 |
| Beta | 0.03 |
| Outstanding Shares | 109,958,613 |
Return
| Return on Equity | -53.27% |
|---|---|
| Return on Assets | -31.70% |
| Return on Invested Capital | -43.76% |
Valuation & Multiples
| P/E Ratio | -4.99 |
|---|---|
| PEG | 18.39 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 8.36 |
| Enterprise Value to EBIT | -3.59 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 0.39 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$4.56 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.11
Average shareholder expectationRevenue Estimate
$3.84 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 13,700▼ 71.58% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 33.30%▼ 2.77% |
|---|---|
| Total Invested | $56.84M▼ 24.27% |
| Investors Holding | 69▲ 2.00% |
ESG Score
No data
About ProQR Therapeutics N.V
CEO: Daniel De Boer